Have you heard about induced pluripotent stem cells (iPS cells), but don’t know exactly what they are and what they can do? If so, read on to learn the answers to frequently asked questions (FAQs) about iPS cells.
In this article:
Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics
Fujifilm CDI is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.
The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
Historic Patent Challenges to Pluripotent Stem Cells (ESCs and iPSCs)
The patent landscape for pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), is characterized by groundbreaking discoveries, legal challenges, and debates over accessibility. The patent environment surrounding these stem cell types is complicated, and there are a number of restrictions on how the cells can be used for commercial and strategic purposes. [Read more…]
Cartherics Wins ‘Most Promising iPSC Therapy Pipeline in APAC’ at Asia Pacific Cell & Gene Therapy Excellence Awards
Melbourne, Australia, 11 September 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is proud to announce that it has been named ‘Most Promising iPSC Therapy Pipeline in APAC’ in the Asia Pacific Cell & Gene Therapy Excellence Awards 2025 (APCGTEA 2025). [Read more…]
Shineco Establishes Biological Cell Digital Division to Integrate iPSC Technology Assets with Blockchain Technology
BEIJING, Aug. 13, 2025 — Shineco Inc. (NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, announced the establishment of a Biological Cell Digital Business Division (the “Division”), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new architecture of blockchain-based cell assets, Shineco aims to build a vertical ecosystem within the biological cell sector, accelerate the global distribution of biological cell products and boost global sales. [Read more…]
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 79
- Next Page »